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Background: Elevated cholesterol in type 2 diabetes mellitus (DM) can cause endothelial dysfunction. An effective
clinical therapy to improve endothelial dysfunction remains to be established. Different cardiovascular actions
between treatments for the inhibition of cholesterol absorption and the suppression of cholesterol synthesis for
achieving improvement in endothelial function are unknown in DM.
Methods: Stable patients with type 2 DM and mildly elevated low-density lipoprotein cholesterol were enrolled. We
evaluated peripheral microvascular endothelial function using reactive hyperemia peripheral arterial tonometry (RH-PAT)
examination and calculated a natural logarithmic transformed value for the RH-PAT index (LnRHI). We randomly assigned
33 patients to each monotherapy: cholesterol synthesis suppression using atorvastatin (5 mg/day, n= 16) or cholesterol
absorption inhibition using ezetimibe (10 mg/day, n= 17). Patients were prospectively followed for 6 months. Serum lipids
and LnRHI were repeatedly examined before and after each therapy.
Results: LDL significantly decreased in both groups, but the percent changes of LDL showed a greater decrease
in the atorvastatin group compared with the ezetimibe group (−34.5 ± 7.8% vs. −21.9 ± 9.6%, p < 0.01). Serum
levels of non-esterified free fatty acids (NEFA) significantly decreased in the ezetimibe group but not in the
atorvastatin group (ezetimibe group: 561.1 ± 236.8 to 429.7 ± 195.9, p < 0.01; atorvastatin group: 538.8 ± 319.5 to
520.2 ± 227.3, p = 0.75). The percent decrease in NEFA was significantly greater in the ezetimibe group
compared with the atorvastatin group (−19.9 ± 27.4% vs. 11.3 ± 44.1%, p < 0.05). LnRHI showed a significant
increase in the ezetimibe group but not in the atorvastatin group (ezetimibe group: 0.471 ± 0.157 to 0.678 ±
0.187, p < 0.01; atorvastatin group: 0.552 ± 0.084 to 0.558 ± 0.202, p = 0.64). The percent changes in LnRHI were
significantly greater in the ezetimibe group compared with the atorvastatin group (63.3 ± 89.2% vs. 7.4 ± 41.2%,
p < 0.05).
Conclusions: In patients with type 2 DM, ezetimibe monotherapy significantly reduced LDL and NEFA, and
improved peripheral microvascular endothelial dysfunction. Ezetimibe could potentially exhibit beneficial
effects on lipid disorders and microvascular endothelial dysfunction in DM.
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Type 2 diabetes mellitus (DM) is a high-risk clinical con-
dition for cardiovascular disease [1]. Treatment strat-
egies that may exhibit favorable effects on cardiovascular
function are thought to have additionally beneficial clin-
ical value in DM. Vascular endothelial dysfunction is a
significant and independent predictor of future cardio-
vascular events [2], and the presence of DM and ele-
vated low-density lipoprotein cholesterol (LDL) are
recognized as important pathological conditions leading
to endothelial dysfunction in clinical practice [3]. In pa-
tients with endothelial dysfunction, it has been reported
that improvement in endothelial function with optimal
medical treatments successfully improved cardiovascular
prognosis in patients with coronary artery disease [4];
however, an effective treatment strategy to improve
endothelial dysfunction is still uncertain in DM [3,5]. In-
creased attention has been focused on investigating and
developing practical strategies for improving vascular
endothelial function clinically [3]. Reactive hyperemia
peripheral arterial tonometry (RH-PAT) is a simple, easy,
non-invasive, and reproducible physiological examin-
ation for testing peripheral microvascular endothelial
function in the fingertip [6,7]. We previously reported
the clinical utility and significance of RH-PAT testing in
terms of prognostic value [8,9], and on the interven-
tional effects in patients with risk factors for cardiovas-
cular disease [10,11].
LDL-lowering therapy is a promising and effective
strategy for preventing atherothrombotic events in high-
risk patients, and has been established as effective in
DM [12]. There are two strategies to reduce LDL in clin-
ical practice [1]: (1) suppression of endogenous choles-
terol synthesis in the liver by statins; and (2) inhibition
of cholesterol absorption in the intestine through block-
ing Niemann-Pick C1-Like 1 (NPC1L1) using ezetimibe
[2]. Statins are generally better at lowering LDL than
ezetimibe, but the clinical difference of both on cardio-
vascular function is not well investigated in DM.
The benefits of statins for patients with DM have been
established in large-scale clinical trials [3]. However, there
is a recent concern that statins may have an adverse effect
on glucose metabolism [4]. Thus, re-evaluation of the com-
prehensive systemic benefits of LDL-lowering therapy in
DM requires careful consideration and is of clinical import-
ance [1]. Ezetimibe has been shown to reduce LDL [2] and
ameliorate postprandial dyslipidemia [5] without adversely
affecting glucose metabolism [1,6,7]. This suggests its po-
tential appropriate usefulness for improving cardiovascular
function and in pathological conditions in DM [8,9].
We hypothesized that ezetimibe monotherapy, as com-
pared with atorvastatin monotherapy, as the LDL-lowering
therapy could significantly improve microvascular endothe-
lial dysfunction in patients with DM. To test this hypothesis,we prospectively enrolled stable patients with type 2 DM
and mildly elevated LDL. Participants were randomly
assigned to either ezetimibe or atorvastatin monotherapy
and were studied for 6 months for the effects of the treat-
ments on peripheral microvascular endothelial function
assessed by RH-PAT examination.
Methods
Study population and study protocol
This was a single center, prospective, open-label, ran-
domized, two-arm clinical trial to investigate the inter-
and intra-group differences of the two strategies for
LDL-lowering therapy on peripheral microvascular
endothelial function in stable patients with type 2 DM.
We primarily recruited lipid-lowering medication
naïve patients with type 2 DM and mildly elevated
LDL (LDL >120 mg/dL) through the outpatient clinic
at Jinnouchi Hospital in Japan. We excluded patients
with unstable conditions, coronary artery disease,
stroke, cancer, active inflammation, autoimmune dis-
ease, lung disease, severe liver disease, and end-stage
renal dysfunction. Patients were randomly allocated by
using permuted-block randomization of six to either
the ezetimibe group (10 mg/day) as the cholesterol ab-
sorption inhibition therapy or the atorvastatin group
(5 mg/day) as the cholesterol synthesis suppression
therapy for 6 months. We repeatedly measured serum
lipid concentrations and peripheral microvascular
endothelial function before and after each therapy at
the outpatient clinic at Jinnouchi Hospital. We did not
change the anti-diabetic medication during the study
period.
This study was conducted in accordance with the prin-
ciples contained in the Declaration of Helsinki. The
study protocol was approved by the Human Ethics Re-
view Committee of Jinnouchi Hospital. Signed consent
was obtained from each participant.
Assessment of peripheral microvascular endothelial
function
The principles and details of RH-PAT examination have
been described previously [10,11]. Briefly, we volumet-
rically evaluated peripheral microvascular endothelial
function in the fingertip by RH-PAT using the Endo-
PAT2000 device (Itamar Medical, Israel). Measurements
were taken when patients were in a stable condition and
in the fasting state in the early morning before taking
their medication. Patients were examined on a bed in
the supine position after at least 10 min of rest in a
temperature- and light-controlled environment. A blood
pressure cuff was placed on the upper arm to be studied,
while the contra-lateral arm served as a control. PAT
probes were placed on one finger of each hand. After an
equilibration period, baseline pulse volume amplitude
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inflated to 60 mmHg above systolic pressure or
200 mmHg for 5 min before being deflated to induce re-
active hyperemia. After cuff deflation, PAT recordings
were made for 10 min and RH-PAT data were automat-
ically analyzed in real time using computer software
(Endo-PAT2000 software, version 3.0.4). The RH-PAT
index (RHI) reflects the extent of reactive hyperemia
and was calculated as the ratio of the average amplitude
of the PAT signal over 1 min starting 1.5 min after cuff
deflation (control arm, A; occluded arm, C) divided by
the average amplitude of the PAT signal in the 2.5 min
before cuff inflation (baseline: control arm, B; occluded
arm, D) according to the equation (C/D)/(A/B) [10]. We
calculated the natural logarithmic transformation (Ln) of
the RHI values, the LnRHI [12]. We were able to
minimize intra- and inter-observer variability as RH-
PAT measurements were analyzed with a computerized
and automated algorithm in an operator-independent
manner [13]. Previous studies have demonstrated that
RH-PAT technology has excellent reproducibility
[13,14].
Blood tests
Fasting blood samples were collected from the antecubital
vein in the morning before the therapies and after the
6 months of treatment with ezetimibe or atorvastatin.
Blood analyses were conducted at the hospital laboratory
for the measurement of blood glucose, hemoglobin A1c
(HbA1c), cholesterol, and triglyceride. Blood lathosterol,
campesterol, and non-esterified free fatty acid (NEFA)
were measured by SRL Corp., Tokyo, Japan. Serum total
cholesterol, triglyceride and NEFA were measured by en-
zymatic methods, and high-density lipoprotein (HDL) and
LDL were measured by direct methods using commercial
reagents (Sekisui Medical Co. Ltd., Tokyo). Fasting plasma
glucose (FPG) was measured by the hexokinase method
and HbA1c was measured by the latex agglutination im-
munoassay. Campesterol and lathosterol were determined
by gas chromatography.
Statistical analysis
Based on our preliminary examination at our hospital,
power analysis indicated that an enrollment of 30 pa-
tients was required to detect a mean difference in per-
cent change in LnRHI 20 ± 12% in the ezetimibe group
and 10 ± 6% in the atorvastatin group, with a power of
80% and a two-sided alpha of 0.05. The results of the
normally distributed continuous variables (determined
by the Shapiro–Wilk test) are expressed as mean (stand-
ard deviation), while those of the continuous variables
with skewed distributions are expressed as median
values (interquartile range). Differences in baseline char-
acteristics of the two groups were analyzed using theStudent’s t-test, the Mann–Whitney U test or the
Fisher’s exact test for categorical data, as appropriate. Ei-
ther the paired Student’s t-test or the Wilcoxon test was
used to analyze the effect of each treatment in intra-
group analysis. The percent changes in LnRHI between
the ezetimibe group and the atorvastatin group were fur-
ther evaluated by analysis of variance (ANOVA) with ad-
justment for age, gender, and body mass index (BMI).
Logistic regression analysis was used to evaluate the as-
sociation between improvement in endothelial function
(LnRHI increase >40%, the highest tertile) and baseline
clinical variables, including age, gender, BMI, HbA1c,
FPG, lipid parameters, medications, and LDL-lowering
therapy allocation (ezetimibe or atorvastatin). Associa-
tions between groups and all other parameters were ana-
lyzed first by univariate logistic regression analysis,
followed by multivariate logistic regression analysis using
the forced inclusion model, and the Hosmer–Lemeshow
goodness-of-fit statistic was calculated. To determine
the relationship between changes in various clinical pa-
rameters and percent changes in LnRHI, correlations be-
tween variables of interest were analyzed using Pearson’s
correlation coefficient. A p-value <0.05 was considered
statistically significant. Statistical analyses were per-
formed using the Statistical Package for Social Sciences,
version 19 (SPSS Inc., IBM, Tokyo, Japan) and SAS, ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline clinical characteristics
The study comprised 33 stable Japanese patients with
type 2 DM and mildly elevated LDL (LDL: 142 ±
21.7 mg/dL). Clinical baseline characteristics of patients
and each group are shown in Table 1. Baseline charac-
teristics of patients in the ezetimibe group were similar
to those of the atorvastatin group. Baseline levels of
BMI, HbA1c, FPG, total cholesterol, LDL, HDL, trigly-
ceride, and NEFA were not significantly different be-
tween groups. There was no significant difference in
peripheral microvascular endothelial function assessed
by LnRHI values in the RH-PAT examination between
groups at baseline (Table 2).
Changes in HbA1c, FPG, and blood lipid parameters
All patients presented with non-significant changes in
HbA1c (7.1 ± 0.9% to 7.1 ± 0.9%, p = 0.98) and FPG (133.7 ±
21.2 to 136.4 ± 26.4 mg/dL, p = 0.47). Intra-group changes
in HbA1c and FPG were not statistically significant in both
groups during therapies. As shown in Table 2, total choles-
terol and LDL significantly decreased in both groups, but
decreases in total cholesterol and LDL were significantly
greater in the atorvastatin group than in the ezetimibe group
(total cholesterol: −22.8 ± 6.1% vs. −17.1 ± 9.3%, p < 0.05;
LDL: −34.5 ± 7.8% vs. −21.9 ± 9.6%, p < 0.01). NEFA
Table 1 Baseline clinical characteristics
Ezetimibe (n = 17) Atorvastatin (n = 16) p-value
Age (years) 64.2 ± 9.8 65.0 ± 8.0 0.81
Sex, male (%) 7 (41.2%) 8 (50.0%) 0.73
Body mass index (kg/m2) 22.5 ± 2.4 23.3 ± 3.5 0.45
Hypertension (%) 9 (56.3%) 9 (52.9%) 1.00
Current smoking (%) 4 (23.5%) 4 (25.0%) 1.00
Hemoglobin A1c (%) 7.3 ± 1.1 6.9 ± 0.6 0.18
Fasting plasma glucose (mg/dL) 135.8 ± 21.5 131.4 ± 21.4 0.57
Duration of diabetes (yeas) 13.6 ± 8.1 11.9 ± 9.3 0.58
Total cholesterol (mg/dL) 237.5 ± 25.8 226.6 ± 29.5 0.27
LDL cholesterol (ng/mL) 148.8 ± 22.1 135.6 ± 19.7 0.08
HDL cholesterol (mg/dL) 57.0 ± 11.3 54.9 ± 19.0 0.71
Triglyceride (mg/dL) 112.0 (100.0–192.5) 134.5 (76.3–229.3) 0.83
Anti-diabetic medicines - - -
Sulfonylureas (%) 2 (11.8%) 5 (31.5%) 0.23
Metformin (%) 5 (29.4%) 4 (25.0%) 1.00
Alpha-glucosidase inhibitor (%) 5 (29.4%) 6 (37.5%) 0.72
Thiazolidinedione (%) 1 (5.9%) 2 (12.5%) 0.60
Glinide (%) 0 (0%) 1 (6.3%) 0.49
DPP-4 inhibitor (%) 1 (5.9%) 2 (12.5%) 0.60
Insulin (%) 8 (47.1%) 3 (18.8%) 0.14
Any anti-diabetic medications (%) 14 (82.3%) 14 (87.5%) 0.53
LnRHI 0.471 ± 0.157 0.552 ± 0.084 0.076
LDL: low-density lipoprotein, HDL: high-density lipoprotein, DPP-4: dipeptidyl peptidase-4, LnRHI: natural logarithmic transformed value of reactive hyperemia
peripheral tonometry index.
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atorvastatin group (Table 2). The percent decrease in NEFA
was significantly greater in the ezetimibe group compared
with the atorvastatin group (−19.9 ± 27.4% vs. 11.3 ± 44.1%,
p < 0.05; Table 2 and Figure 1). Campesterol, as the choles-
terol absorption marker, significantly decreased in the ezeti-
mibe group but not in the atorvastatin group. Lathosterol,
as the cholesterol synthesis marker, significantly decreased
in the atorvastatin group and increased in the ezetimibe
group. The lathosterol to campesterol ratio, as the compre-
hensive indicator of cholesterol synthesis and absorption
balance, exhibited a significant increase in the ezetimibe
group and a significant decrease in the atorvastatin group.
The percent change in the lathosterol to campesterol ratio
was significantly different between the two groups (ezeti-
mibe group: 239.3 ± 38.5%, atorvastatin-group: −39.2 ±
38.5%, p < 0.001; Table 2 and Figure 2).
Changes in peripheral microvascular endothelial function
assessed by LnRHI
During the 6-month treatments, microvascular endothe-
lial function assessed by LnRHI significantly improvedafter LDL-lowering therapy in all patients (LnRHI: 0.510 ±
0.131 to 0.630 ± 0.198, p = 0.01). Ezetimibe monotherapy
but not atorvastatin monotherapy exhibited a significant
intra-group improvement in peripheral microvascular
endothelial function assessed by LnRHI (ezetimibe group:
0.471 ± 0.157 to 0.678 ± 0.187, p < 0.01; atorvastatin group:
0.552 ± 0.084 to 0.558 ± 0.202, p = 0.64; Table 2). Regarding
inter-group comparisons, the percent changes in LnRHI
were significantly greater in the ezetimibe group compared
with the atorvastatin group (p = 0.028; Table 2 and Figure 3).
After using ANOVA with adjustment for age, gender, and
BMI, the percent changes in LnRHI were significantly
greater in the ezetimibe group compared with the atorva-
statin group (ANOVA, p = 0.041).
Univariate logistic regression analysis for various
clinical factors demonstrated that only ezetimibe ther-
apy significantly correlated with improvements in per-
ipheral microvascular endothelial function defined as
the highest tertile of the percent changes in LnRHI
(Table 3, odds ratio: 4.88, 95% confidence interval:
1.01–23.57, p = 0.049). Forced inclusion multivariate
logistic regression analysis with age, gender, and the
Figure 1 Percent changes in NEFA with atorvastatin and ezetimibe
therapies. Percent changes in NEFA = (post-NEFA - pre-NEFA) × 100 /
pre-NEFA. Bar graphs represent data of mean and standard error of
mean. Atorvastatin group (n = 16) and ezetimibe group (n = 17).
NEFA: non-esterified free fatty acid.
Figure 2 Percent changes in lathosterol/campesterol with
atorvastatin and ezetimibe therapies. Percent changes in
lathosterol/campesterol = (post-lathosterol/campesterol - pre-
lathosterol/campesterol) × 100 / pre-lathosterol/campesterol. Bar
graphs represent data of mean and standard error of mean.
Atorvastatin group (n = 16) and ezetimibe group (n = 17).
Table 2 Changes in diabetes and lipid parameters and LnRHI
Ezetimibe (n = 17) p − value Atorvastatin (n = 16) p − value
Baseline 6 months Baseline 6 months
Hemoglobin A1c (%) 7.3 ± 1.1 7.5 ± 0.8 0.307 6.9 ± 0.6 6.7 ± 0.7 0.062
% change (%) 3.9 ± 13.3 −0.3 ± 2.1
Fasting plasma glucose (mg/dL) 135.8 ± 21.5 135.8 ± 27.9 0.581 131.4 ± 21.4 133.9 ± 25.5 0.651
% change (%) 2.6 ± 15.3 2.8 ± 7.8
Total cholesterol (mg/dL) 237.5 ± 25.8 195.7 ± 21.6 <0.001 226.6 ± 29.5 174.4 ± 22.2 <0.001
% change (%) −17.1 ± 9.3‡ −22.8 ± 6.1‡
LDL cholesterol (mg/dL) 148.8 ± 22.1 115.5 ± 17.9 <0.001 135.6 ± 19.7 88.9 ± 17.5 <0.001
% change (%) −21.9 ± 9.6* −34.5 ± 7.8*
HDL cholesterol (mg/dL) 57.0 ± 11.3 54.9 ± 12.6 0.31 54.9 ± 19.0 58.0 ± 18.5 0.035










% change (%) −8.9 ± 28.1 −7.0 ± 45.0
NEFA (mg/dL) 561.1 ± 236.8 429.7 ± 195.9 0.009 538.8 ± 319.5 520.2 ± 227.3 0.746
% change (%) −19.9 ± 27.4‡ 11.3 ± 44.1‡
Lathosterol (μg/mL) 3.30 ± 1.45 4.60 ± 1.96 0.004 3.44 ± 1.52 1.57 ± 0.61 <0.001
% change (%) 51.2 ± 52.2* −42.0 ± 49.7*
Campesterol (μg/mL) 6.14 ± 2.74 2.69 ± 0.72 <0.001 6.56 ± 1.53 6.21 ± 1.86 0.217










% change (%) 239.3 ± 38.5* −39.2 ± 38.5*
LnRHI 0.471 ± 0.157 0.678 ± 0.187 0.007 0.552 ± 0.084 0.558 ± 0.202 0.645
% change (%) 63.3 ± 89.2‡ 7.4 ± 41.2‡
LDL: low-density lipoprotein, HDL: high-density lipoprotein, NEFA: non-esterified fatty acid, LnRHI: natural logarithmic transformed value of reactive hyperemia
peripheral tonometry index. * p < 0.001, ‡ p < 0.05; ezetimibe vs. atorvastatin.
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Figure 3 Percent changes in LnRHI with atorvastatin and ezetimibe
therapies. Percent changes in LnRHI = (post-LnRHI - pre-LnRHI) × 100 /
pre-LnRHI.Bar graphs represent data of mean and standard error of
mean. Atorvastatin group (n= 16) and ezetimibe group (n= 17). LnRHI:
natural logarithmic transformed value of reactive hyperemia peripheral
arterial tonometry index.
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ezetimibe therapy significantly correlated with im-
provements in endothelial function (Table 3, odds ra-
tio: 6.42, 95% confidence interval: 1.13–36.47, p =
0.036). The Hosmer–Lemeshow statistic was appropri-
ate (p = 0.53).Table 3 Logistic regression analysis of baseline parameters fo
Baseline variable Univariate regression
OR 95% CI p
Age (per year) 1.02 0.94–1.11 0.58
Gender (male) 2.28 0.54–9.67 0.27
Body mass index (per 1.0) 1.06 0.83–1.36 0.66
Hemoglobin A1c (per 0.1; %) 0.98 0.89–1.04 0.33
Fasting plasma glucose (per 1.0; mg/dl) 0.98 0.94–1.01 0.17
Total cholesterol (per 1.0; mg/dl) 0.99 0.97–1.03 0.96
LDL cholesterol (per 1.0; mg/dl) 0.98 0.95–1.01 0.21
HDL cholesterol (per 1.0; mg/dl) 1.01 0.96–1.06 0.72
Triglyceride (per 1.0; mg/dl) 1.01 0.99–1.02 0.20
Sulfonylureas (yes) 1.42 0.26–7.76 0.69
Metformin (yes) 1.60 0.34–7.65 0.56
Alpha-glucosidase inhibitor (yes) 0.54 0.11–2.62 0.45
Thiazolidinedione (yes) 0.86 0.07–1.66 0.91
Glinide (yes) 1.00 0.00–— 1.00
DPP4 inhibitor (yes) 0.86 0.07–10.66 0.91
Insulin (yes) 1.74 0.40–7.91 0.45
Ezetimibe-therapy (yes) 4.88 1.01–23.57 0.04
LnRHI: natural logarithmic transformed value of reactive hyperemia peripheral tonometry
high-density lipoprotein, DPP-4, dipeptidyl peptidase-4; Hosmer–Lemeshow p= 0.53 in mCorrelation between percent changes in LnRHI and
various lipid parameters
To determine the associated factors between the LDL-
lowering therapy-induced improvement in microvascular
endothelial function and changes in lipid parameters, we
investigated the correlation coefficient between percent
changes in LnRHI and percent changes in plasma lipid
variables during therapy. As shown in Table 4, percent
changes in LnRHI did not significantly correlate with
percent changes in total cholesterol, LDL, HDL, and tri-
glyceride. Changes in LnRHI showed significant correla-
tions with changes in cholesterol absorption or synthesis
parameters during therapy (Table 4). The indicator of
cholesterol synthesis and absorption balance (the ratio
of lathosterol to campesterol) demonstrated the greatest
correlation efficient value (r = 0.459, p = 0.008) among all
parameters. In the intra-group analyses, none of the pa-
rameters were significantly correlated with percent
changes in LnRHI in the ezetimibe and atorvastatin
groups (Tables 5 and 6).
Discussion
This is the first study to directly investigate the effectiveness
of two different LDL-lowering strategies, cholesterol ab-
sorption inhibition and cholesterol synthesis suppression,
on microvascular endothelial function in type 2 DM. We
observed that ezetimibe monotherapy, when compared
with atorvastatin monotherapy, significantly decreasedr the improvement of LnRHI (>40%)
Multivariate regression using forced inclusion model

















9 6.42 1.13–36.47 0.036
index; OR, odds ratio; CI, confidence interval; LDL, low-density lipoprotein; HDL,
ultivariate analysis.
Table 4 Correlation between percent changes in lipid
parameters and percent changes in LnRHI in all subjects
r p-value
Percent change in total cholesterol −0.053 0.769
Percent change in LDL cholesterol −0.053 0.770
Percent change in HDL cholesterol −0.222 0.215
Percent change in triglyceride 0.236 0.186
Percent change in NEFA −0.115 0.524
Percent change in lathosterol 0.354 0.047
Percent change in campesterol −0.399 0.024
Percent change in lathosterol/campesterol 0.459 0.008
LDL: low-density lipoprotein, HDL: high-density lipoprotein, NEFA: non-
esterified fatty acid, LnRHI: natural logarithmic transformed value of reactive
hyperemia peripheral tonometry index.
Table 6 Correlation between percent changes in lipid
parameters and in LnRHI in subjects treated by
atorvastatin
r p-value
Percent change in total cholesterol −0.106 0.696
Percent change in LDL cholesterol −0.420 0.105
Percent change in HDL cholesterol 0.276 0.300
Percent change in triglyceride 0.438 0.065
Percent change in NEFA −0.055 0.893
Percent change in lathosterol −0.180 0.504
Percent change in campesterol −0.098 0.723
Percent change in lathosterol/campesterol −0.121 0.655
LDL: low-density lipoprotein, HDL: high-density lipoprotein, NEFA: non-
esterified fatty acid, LnRHI: natural logarithmic transformed value of reactive
hyperemia peripheral tonometry index.
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microvascular endothelial function using RH-PAT tests in
stable patients with type 2 DM.
In patients with type 2 DM, lowering cholesterol using
statins is clinically effective and is an established treat-
ment for preventing cardiovascular events [3]. However,
there are no clinical studies comparing the effects of
LDL-lowering monotherapies, such as cholesterol syn-
thesis suppression using statins or cholesterol absorption
inhibition using ezetimibe, on endothelial function in pa-
tients with type 2 DM.
In the small intestine, cholesterol is absorbed through
NPC1L1, the target molecule of ezetimibe [2]. Ezetimibe
exhibits its LDL-lowering properties by blocking
NPC1L1 in the small intestine without attenuating the
mevalonate pathway [2]. Recently, it has been reported
that inactivating mutations in the NPC1L1 gene pro-
vided significant protection against coronary heart dis-
ease [15]. It has also been reported that intestinal
expression of NPC1L1 increased in patients with type 2
DM [16]. Additionally, the LDL-lowering effect of ezeti-
mibe was significantly greater in DM [17], suggestingTable 5 Correlation between percent changes in lipid
parameters and in LnRHI in subjects treated by ezetimibe
r p-value
Percent change in total cholesterol −0.246 0.336
Percent change in LDL cholesterol −0.375 0.138
Percent change in HDL cholesterol −0.220 0.397
Percent change in triglyceride 0.150 0.565
Percent change in NEFA 0.137 0.601
Percent change in lathosterol 0.283 0.289
Percent change in campesterol −0.273 0.306
Percent change in lathosterol/campesterol 0.324 0.221
LDL: low-density lipoprotein, HDL: high-density lipoprotein, NEFA: non-
esterified fatty acid, LnRHI: natural logarithmic transformed value of reactive
hyperemia peripheral tonometry index.the potentially beneficial role of ezetimibe as a NPC1L1
inhibitor in the treatment of DM with dyslipidemia and
vascular dysfunction [8,9].
In the present study, each monotherapy resulted in a
significant decrease in blood LDL, but the marker of the
cholesterol synthesis/absorption balance showed a mark-
edly different effect. We confirmed that the two treat-
ments had opposite effects on endogenous metabolism
of cholesterol synthesis/absorption, and found that
changes in the cholesterol synthesis/absorption balance
significantly correlated with changes in microvascular
endothelial function in patients with DM. Interestingly,
the effect of each monotherapy on peripheral micro-
vascular endothelial function in patients with DM varied
significantly. Ezetimibe monotherapy but not atorva-
statin monotherapy significantly improved peripheral
microvascular endothelial function. Effective cardiovas-
cular actions through the inhibition of cholesterol ab-
sorption by ezetimibe would be clinically expected in
DM [9].
Previously, Nochioka et al. reported that ezetimibe,
when compared with pravastatin, significantly improved
endothelial function as assessed by flow-mediated dila-
tion (FMD) in young healthy volunteers [18]. The re-
searchers identified a significant correlation between the
reduction of a cholesterol absorption marker and im-
provement in FMD. In outpatients with type 2 DM,
we found similar clinical results in the present study.
Recently, the effect of pravastatin or ezetimibe on
endothelial function was reported as evaluated by
FMD in non-DM patients with hypercholesterolemia
[19]. The researchers concluded that LDL-lowering by
pravastatin or ezetimibe induced similar effects on
vascular endothelial function improvement, and they
suggested that the pleiotropic effects of statins were
not important for improvement in vascular endothelial
function. Although the LDL decrease was equal in the
Sugiyama et al. Lipids in Health and Disease  (2015) 14:37 Page 8 of 10two treatment strategies in that study, the improve-
ment in FMD tended to be greater with ezetimibe than
with pravastatin (FMD change: ezetimibe 5.2% vs.
pravastatin 3.8%), indicating the potentially beneficial
use of ezetimibe. The major differences between that
study and the present study are the baseline clinical
backgrounds of patients (non-DM vs. DM and hyper-
cholesterolemia [LDL: 180 mg/dL] vs. mildly elevated
cholesterol [LDL: 142 mg/dL]), treatment period
(6 weeks vs. 6 months), and the method of assessing
endothelial function (FMD vs. RH-PAT). Several previ-
ous studies failed to demonstrate the beneficial effect
of ezetimibe monotherapy on endothelial function
[20-22]. These studies compared the effects of statin
or ezetimibe on endothelial function in patients with
heart failure [20,21] or coronary artery disease with a
small number of patients with DM [22], and the
authors mentioned the ‘pleiotropic effect of statin’ for
the treatment of cardiovascular disease. In contrast,
Yunoki et al. reported the improvement achieved by
ezetimibe on endothelial dysfunction in the postpran-
dial phase [23] and in CAD patients with hypertriglyc-
eridemia [24]. Moreover, Yamaoka-Tojo et al. reported
the benefit of the add-on therapy of ezetimibe to statin
therapy in patients at high risk of cardio-metabolic
disease [25].
In the present study, atorvastatin did not significantly
improve microvascular endothelial function in DM, al-
though there was a greater reduction in LDL. The reason
why atorvastatin did not improve endothelial function is
unclear. Several clinical studies reported that statins
could improve endothelial function in patients with DM
[26-28]. In contrast, several randomized trials showed
that statins did not improve endothelial function in
patients with type 2 DM [29-32]. Recently, Zhang et al.
reported a meta-analysis of placebo randomized studies
using FMD as the measure of endothelial function to
determine the effects of statins on endothelial function in
patients with DM [33]. They found overall beneficial
effects of statins on endothelial function in patients with
DM but the beneficial effects were not observed in
patients with type 2 DM, obesity (BMI > 27), and older
age (>55 years) in the sub-analysis. In the present study,
all of the enrolled patients had type 2 DM and average
age of 64.6 years. Thus, we speculated that our patients
could be less responsive to statin therapy in terms of
endothelial function improvement.
In the present study, we investigated the effects of eze-
timibe and atorvastatin on the peripheral microvascular
endothelial function assessed by RH-PAT. We focused
mainly on the microcirculation rather than the large
conduit arteries, such as the brachial artery that was
used for the FMD measurement. Regarding the effect of
statins on microvascular endothelial function, previousstudies reported that there was no significant benefit of
statin therapy in patients with DM [34-37]. This study is
the first to report the improvement of microvascular
endothelial dysfunction by ezetimibe in patients with
type 2 DM.
Because LDL-lowering therapy is essential and effect-
ive for patients with DM in the clinical practice, we can-
not conduct a placebo-controlled study with statin
therapy for DM. We think that the results of the present
study will shed light on the controversial subject of
endothelial dysfunction therapy in patients with DM.
Further studies evaluating larger numbers of DM cases
are required to confirm the results of the present study.
The clinical properties of ezetimibe for the treatment
of dyslipidemia are improvements in both hypercholes-
terolemia and postprandial dyslipidemia [2,38]. In the
present study, we identified, for the first time, that ezeti-
mibe significantly reduced NEFA in patients with DM. It
has been reported that ezetimibe can significantly reduce
fatty acid absorption in animal models [39], that NEFA is
involved in the pathological conditions of insulin resist-
ance [40], and that NEFA is associated with inflammation
[41,42] and endothelial dysfunction [43]. These findings
suggest that NEFA could have great significance in the
pathological conditions of DM [44]. In the present study,
ezetimibe significantly reduced NEFA in patients with
DM, but statin did not have the similar effect. Changes in
NEFA might bring about different effects on the long-
term metabolic balance of lipids and glucose [43]. A po-
tential therapy to significantly reduce NEFA in DM has
not been reported until now, and we think that this result
has important clinical meaning. The impact of ezetimibe-
mediated changes in NEFA on vascular endothelial func-
tion requires further detailed examination.
Both ezetimibe and atorvastatin therapy resulted in sig-
nificant reductions of LDL; however, ezetimibe significantly
improved endothelial function compared to atorvastatin.
This finding suggests that ezetimibe added on to the LDL-
lowering effects by an unknown mechanism, and this
unique property might contribute to the improvement of
endothelial function in patients with DM. It has been re-
ported that a postprandial metabolic disorder is deeply in-
volved in endothelial dysfunction in DM, and ezetimibe
improved postprandial hyperlipemia and its induced endo-
thelial dysfunction [23]. We did not measure postprandial
lipid parameters in the present study, but we can speculate
that the ezetimibe-mediated improvement in postprandial
dyslipidemia may potentially contribute to the beneficial
vascular function. In a future study, we need to investigate
the correlation between ezetimibe-mediated improvement
of postprandial dyslipidemia and endothelial function in pa-
tients with DM.
Recent meta-analysis demonstrated that the statin-
mediated increase in HDL might not be significantly
Sugiyama et al. Lipids in Health and Disease  (2015) 14:37 Page 9 of 10associated with the decrease in future cardiovascular
events [45]. Regarding HDL, it has been reported that
not only plasma quantity of HDL, but also functional
quality of HDL is important for exerting vascular pro-
tective and anti-atherosclerotic effects [46]. In the
present study, the HDL increase by atorvastatin was not
associated with improvement of endothelial function in
patients with DM. It will be worth to determine whether
ezetimibe could modulate HDL function in a future
study. Based on the present results, we think that
changes in HDL by LDL-lowering therapy cannot be
good indicators of improvement of microvascular endo-
thelial function in patients with DM.
This study had several limitations. The study was a
single center study and the protocol was open-labeled.
Only a small number of patients made up the study
population, and the study period was short. We did not
evaluate serum levels of postprandial lipids and oxy-
sterol. As the study patients were stable and had rela-
tively favorable and controlled type 2 DM, were not
obese, and did not have cardiovascular diseases, further
studies are required using a larger number of patients
with DM with a broad spectrum of clinical backgrounds.
In conclusion, both ezetimibe monotherapy and ator-
vastatin monotherapy significantly reduced LDL, and
ezetimibe monotherapy significantly increased LnRHI in
patients with DM. Ezetimibe, but not atorvastatin, sig-
nificantly reduced serum levels of NEFA. In this popula-
tion of patients with type 2 DM, ezetimibe monotherapy
significantly ameliorated dyslipidemia and improved per-
ipheral microvascular endothelial dysfunction.
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